AMENDMENT AND RESPONSE UNDER 37 CFR § 1.116 – EXPEDITED PROCEDURE

Serial Number: 10/082,925 Filing Date: February 26, 2002

Title: PURIFICATION METHOD

Page 2 Dkt: 697.004US2

IN THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-26. (Canceled)
- 27. (Previously presented) An isolated and purified alpha-1-acid glycoprotein (AAG) having a lipopolysaccharide (LPS) concentration of less than or equal to 0.1 Eu/mg AAG.
- 28. (Previously presented) The AAG of claim 27 wherein the AAG has a LPS level of less than 0.075 Eu/mg AAG.
- 29. (Previously presented) The AAG of claim 27 wherein the AAG has a LPS level of less than 0.050 Eu/mg AAG.
- 30. (Previously presented) A virus inactivated or a virus depleted preparation of the AAG of claim 27.
- 31-33. (Canceled)
- 34. (Previously presented) A pharmaceutical composition comprising the AAG of claim 27 and a pharmaceutically acceptable carrier, excipient, diluent, or combination thereof.
- 35. (Previously presented) The pharmaceutical composition of claim 34, wherein the AAG comprises less than 0.075 Eu LPS/mg AAG.
- 36. (Previously presented) The pharmaceutical composition of claim 35, wherein the AAG

AMENDMENT AND RESPONSE UNDER 37 CFR § 1.116 – EXPEDITED PROCEDURE
Serial Number: 10/082,925
Filing Date: February 26, 2002
Title: PURIFICATION METHOD

Page 3 Dkt: 697.004US2

comprises less than 0.050 Eu LPS/mg AAG.

(Previously presented) The pharmaceutical composition of claim 36, wherein the AAG 37. comprises less than 0.02 Eu LPS/mg AAG.

(Canceled) 38-45.